Enoxaparin Sodium
CAS No.: 679809-58-6 (Low molecular weight heparin)
Short Description:
Source: Extracted from porcine intestinal mucosa and degraded by β-elimination method.
Function and use: By inhibiting coagulation active factor X (FXa) and thrombin (FIIa), heparin pentose structure binds AT-III (antithrombin III), and exerts anticoagulant effect.
Enoxaparin sodium prevents venous thromboembolic disease (prevention of thrombosis in the veins), especially those associated with orthopaedic or general surgery; treats established deep vein thrombosis, with or without pulmonary embolism, clinical Symptoms are not severe, excluding pulmonary embolism requiring surgery or thrombolytic therapy; treatment of unstable angina pectoris and non-Q-wave myocardial infarction, in combination with aspirin; used in hemodialysis cardiopulmonary bypass to prevent thrombosis; treatment of acute ST segment Elevated myocardial infarction, combined with thrombolytics or concurrently with percutaneous coronary intervention (PCI).
Enoxaparin?Sodium-Pharmacopoeia?Standard:?BP/EP
Specification
| Enoxaparin Sodium | ||||
| Source | Intestinal mucosa of pigs | |||
| Quality standard |
USP |
EP |
||
|
characters |
Appearance |
/ |
white or almost white;?hygroscopic powder | |
| solubility |
/ |
freely soluble in water | ||
| identification | The spectra exhibit maxima at 231±2nm | The 13C NMR spectrum obtained is similar to that obtained with the appropriate specific Enoxaparin sodium CRS | ||
| The spectra are similar | 15 -25 % bearing the 1,6-anhydro structure at the reducing end of their chain | |||
| Anti- Xa activity/?anti-?IIa?: 3.3-5.3 | Anti- Xa activity/?anti-?IIa?: 3.3-5.3 | |||
| Mw :?3800?-5000Da, M≤2000?:?12.0%-20.0%,???????????????????????????????M≥8000:NMT 18.0%, M2000-8000:68.0%-82.0% | Mw :?3800?-5000Da, M≤2000?:?12.0%-20.0%,???????????????????????????????M≥8000:NMT 18.0%, M2000-8000:68.0%-82.0% | |||
| Meets the requirements for Sodium Content | It complies with the test for sodium | |||
| Appearance of solution | / | clear；NMT: intensity?6 | ||
| Specific Absorbance | 14.0-20.0 (on the dried basis) | 14.0-20.0 (on the dried basis),determined at 231nm | ||
| pH | 6.2-7.7 | 6.2-7.7 | ||
| Benzyl alcohol | ≤?0.1% | ≤?0.1% | ||
| Molar ratio of Sulfate carboxylate | ≥?1.8 | ≥?1.8 | ||
| Nitrogen | 1.8?%-2.5 %?(on the dried basis) | 1.5 %-2.5 %?(on the dried basis) | ||
| Sodium | 11.3%?-13.5%?(on the dried basis) | 11.3%?-13.5%?(on the dried basis) | ||
| Loss on drying | ≤?10.0% | ≤?10.0% | ||
| Bacterial endotoxins | ＜0.01EU/U | ＜0.01EU/IU | ||
| Assay | Anti- Xa activity | 90-125 IU/mg (on the dried basis) | 90-125 IU/mg (on the dried basis) | |
| Anti- IIa activity | 20-35 IU/mg (on the dried basis) | 20-35 IU/mg (on the dried basis) | ||
CAS No.: 9041-08-1 (Low molecular weight heparin)
CAS No.: 37270-89-6 (Low molecular weight heparin)
